FDA WARNING_LETTER - Effingham Equity - January 31, 2022

FDA WARNING_LETTER for Effingham Equity on January 31, 2022. Product: Food. Access full analysis and detailed observations.

View on Dashboard

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

FDA WARNING_LETTER for Effingham Equity on January 31, 2022. Product: Food. Access full analysis and detailed observations.

Violation Codes

21 CFR 225.42(b)(4)

FD&C Act 501(a)(2)(B)

21 CFR 507.33(a)(1)

21 U.S.C. 331(k)

21 U.S.C. 342(a)(4)

FD&C Act 402(a)(4)

FD&C Act 301(k)

21 U.S.C. 351(a)(2)(B)

21 U.S.C. 331(uu)

21 CFR 507

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Effingham Equity

Inspection Date

January 31, 2022

Product Type

Food

Office

Division of Human and Animal Food Operations - East VI

People

William R. Weissinger (Program Director)

ID: a6b3ecf5-447b-4123-9ec2-c7d78f1dc98a

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox